EVE BIOTEK
EVE BIOTEK
PATHWAY TO DISCOVERY
WHAT WE DO
Computational Drug Development
At Eve BioTek we have developed a proprietary simulation-based drug development platform, and technology that can assess quantitatively the ability of chemical compounds to permeate endothelial barriers such as the blood brain barrier. These in silico
tools for organ exposure and solubility allow screening of pharmacophores before synthesis and accelerate lead optimization, allowing our clients to get promising leads into the clinic quickly and inexpensively by avoiding costly and time-consuming in vitro
assays and animal studies.
Lead
Optimisation
Solubility
Prediction
Organ
Exposure
Consulting
Eve BioTek can help your organisation design a computational platform based on your R&D ambitions.
Contract Work
Eve BioTek can offer a range of services tailored to your company needs, including our first of its kind in silico
drug screening.
Collaborative Drug Development
Eve BioTek can work collaboratively with your company to develop novel therapeutics using our proprietary drug development platform.
WHY EVE?
CHEAPER
Eve BioTek can save you over 90% per compound screen compared to in vivo
studies.
FASTER
Eve BioTek delivers rapid results by screening several compounds in parallel.
SUSTAINABLE
Reduce your use of animals by using Eve BioTek's computational solutions.
WHO WE ARE
We specialise in providing an expert service to meet your scientific needs.
Nils Berglund, PhD
Chief Executive Officer
Martin Ulmschneider, DPhil
Chief Scientific Officer
Rong-I Arthur Hong, DPhil
Chief Strategy Officer
OUR PARTNERS
EVE BIOTEK
